Ferozsons Laboratories Limited

KASE:FEROZ Stock Report

Market Cap: PK₨12.3b

Ferozsons Laboratories Valuation

Is FEROZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FEROZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FEROZ (PKR282.87) is trading above our estimate of fair value (PKR14.47)

Significantly Below Fair Value: FEROZ is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for FEROZ?

Other financial metrics that can be useful for relative valuation.

FEROZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA8.1x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does FEROZ's PE Ratio compare to its peers?

The above table shows the PE ratio for FEROZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average13.7x
CPHL Citi Pharma
11.2xn/aPK₨9.5b
BFBIO BF Biosciences
15.5xn/aPK₨5.8b
HPL Hoechst Pakistan
13.5xn/aPK₨21.8b
HINOON Highnoon Laboratories
14.5xn/aPK₨43.7b
FEROZ Ferozsons Laboratories
19.2xn/aPK₨12.3b

Price-To-Earnings vs Peers: FEROZ is expensive based on its Price-To-Earnings Ratio (19.2x) compared to the peer average (13.7x).


Price to Earnings Ratio vs Industry

How does FEROZ's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: FEROZ is good value based on its Price-To-Earnings Ratio (19.2x) compared to the Asian Pharmaceuticals industry average (25.3x).


Price to Earnings Ratio vs Fair Ratio

What is FEROZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FEROZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate FEROZ's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies